Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene marks risk of VF (ventricular fibrillation) heart attacks:

This article was originally published in Clinica

Executive Summary

Heart attacks due to ventricular fibrillation are linked to genetic abnormalities in patients with no obvious cardiac disease, according to new US research. Mutations in the cardiac sodium channel gene SCN5A are responsible for the attacks - amounting to between 5% and 12% of VF cases. The gene could be used to assess individual risk through genetic testing, says the article (Nature March 19, p 293).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT080887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel